TY  - JOUR
AU  - Sachpekidis, Christos
AU  - Larribère, Lionel
AU  - Kopp-Schneider, Annette
AU  - Hassel, Jessica C
AU  - Dimitrakopoulou-Strauss, Antonia
TI  - Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?315
JO  - Cancer immunology immunotherapy
VL  - 68
IS  - 2
SN  - 1432-0851
CY  - Heidelberg
PB  - Springer
M1  - DKFZ-2018-02087
SP  - 297-303
PY  - 2019
AB  - An association between immune-related adverse events (irAEs) caused by immunotherapeutic agents and the clinical benefit of immunotherapy has been suggested. We retrospectively evaluated by means of 18F-FDG PET/CT lymphoid tissue changes in the mediastinal/hilar lymph nodes and the spleen in response to ipilimumab administration in metastatic melanoma.A total of 41 patients with unresectable metastatic melanoma underwent 18F-FDG PET/CT before the start of ipilimumab (baseline PET/CT), after two cycles (interim PET/CT) and at the end of treatment (late PET/CT). Data analysis was focused on the mediastinal/hilar lymph nodes and the spleen. The patients' best clinical response (BCR) was used as reference.According to the BCR reference, 31 patients showed disease control (DC) and 10 patients showed progressive disease (PD). Mediastinal/hilar lymph node evaluation revealed that in total 4 patients in the interim or late PET/CT (10
LB  - PUB:(DE-HGF)16
C6  - pmid:30478475
DO  - DOI:10.1007/s00262-018-2279-9
UR  - https://inrepo02.dkfz.de/record/141819
ER  -